Translational Hematology and Medical Oncology · Cleveland Clinic Taussig Cancer Institute Department of Translational Hematology and Medical Oncology Journal Publications (2011 to

Cleveland Clinic Taussig Cancer Institute Department of Translational Hematology and Medical Oncology Journal Publications (2011 to date)

Page 1 Last update 12/4/2013

Primary Investigators

Jaroslaw Maciejewski, MD, PhD

Santini V, Melnick A, Maciejewski JP, Duprez E, Nervi C, Cocco L, Ford KG, Mufti G. Epigenetics in focus: Pathogenesis of myelodysplastic syndromes and the role of hypomethylating agents. Crit Rev Oncol Hematol. 2013 Nov;88(2):231-245.

Jerez A, Clemente MJ, Makishima H, Rajala H, Gomez-Segui I, Olson T, McGraw K, Przychodzen B, Kulasekararaj A, Afable M, Husseinzadeh HD, Hosono N, Leblanc F, Lagstrom S, Zhang D, Ellonen P, Tichelli A, Nissen C, Lichtin AE, Wodnar-Filipowicz A, Mufti GJ, List AF, Mustjoki S, Loughran TP, Jr., Maciejewski JP. STAT3 mutations indicate the presence of subclinical T-cell clones in a subset of aplastic anemia and myelodysplastic syndrome patients. Blood. 2013 Oct 3;122(14):2453-2459.

Wenzell CM, Gallagher EM, Earl M, Yeh JY, Kusick KN, Advani AS, Kalaycio ME, Mukherjee S, Tiu RV, Maciejewski JP, Sekeres MA. Outcomes in obese and overweight acute myeloid leukemia patients receiving chemotherapy dosed according to actual body weight. Am J Hematol. 2013 Oct;88(10):906-909.

Gomez-Segui I, Makishima H, Jerez A, Yoshida K, Przychodzen B, Miyano S, Shiraishi Y, Husseinzadeh HD, Guinta K, Clemente M, Hosono N, McDevitt MA, Moliterno AR, Sekeres MA, Ogawa S, Maciejewski JP. Novel recurrent mutations in the RAS-like GTP-binding gene RIT1 in myeloid malignancies. Leukemia. 2013 Sep;27(9):1943-1946.

Przychodzen B, Jerez A, Guinta K, Sekeres MA, Padgett R, Maciejewski JP, Makishima H. Patterns of missplicing due to somatic U2AF1 mutations in myeloid neoplasms. Blood. 2013 Aug 8;122(6):999-1006.

Makishima H, Yoshida K, Nguyen N, Przychodzen B, Sanada M, Okuno Y, Ng KP, Gudmundsson KO, Vishwakarma BA, Jerez A, Gomez-Segui I, Takahashi M, Shiraishi Y, Nagata Y, Guinta K, Mori H, Sekeres MA, Chiba K, Tanaka H, Muramatsu H, Sakaguchi H, Paquette RL, McDevitt MA, Kojima S, Saunthararajah Y, Miyano S, Shih LY, Du Y, Ogawa S, Maciejewski JP. Somatic SETBP1 mutations in myeloid malignancies. Nat Genet. 2013 Aug;45(8):942-946.

Sakaguchi H, Okuno Y, Muramatsu H, Yoshida K, Shiraishi Y, Takahashi M, Kon A, Sanada M, Chiba K, Tanaka H, Makishima H, Wang X, Xu Y, Doisaki



S, Hama A, Nakanishi K, Takahashi Y, Yoshida N, Maciejewski JP, Miyano S, Ogawa S, Kojima S. Exome sequencing identifies secondary mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia. Nat Genet. 2013 Aug;45(8):937-941.

Yip BH, Vuppusetty C, Attwood M, Giagounidis A, Germing U, Lamikanra AA, Roberts DJ, Maciejewski JP, Vandenberghe P, Mecucci C, Wainscoat JS, Pellagatti A, Boultwood J. Activation of the mTOR signaling pathway by L-leucine in 5q- syndrome and other RPS14-deficient erythroblasts. Leukemia. 2013 Aug;27(8):1760-1763.

Mallo M, del Rey M, Ibanez M, Calasanz MJ, Arenillas L, Larrayoz MJ, Pedro C, Jerez A, Maciejewski J, Costa D, Nomdedeu M, Diez-Campelo M, Lumbreras E, Gonzalez-Martinez T, Marugan I, Such E, Cervera J, Cigudosa JC, Alvarez S, Florensa L, Hernandez JM, Sole F. Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations. Br J Haematol. 2013 Jul;162(1):74-86.

Hillmen P, Muus P, Roth A, Elebute MO, Risitano AM, Schrezenmeier H, Szer J, Browne P, Maciejewski JP, Schubert J, Urbano-Ispizua A, De Castro C, Socie G, Brodsky RA. Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol. 2013 Jul;162(1):62-73.

Rhyasen GW, Bolanos L, Fang J, Jerez A, Wunderlich M, Rigolino C, Mathews L, Ferrer M, Southall N, Guha R, Keller J, Thomas C, Beverly LJ, Cortelezzi A, Oliva EN, Cuzzola M, Maciejewski JP, Mulloy JC, Starczynowski DT. Targeting IRAK1 as a therapeutic approach for myelodysplastic syndrome. Cancer Cell. 2013 Jul 8;24(1):90-104.

Ades L, Sekeres MA, Wolfromm A, Teichman ML, Tiu RV, Itzykson R, Maciejewski JP, Dreyfus F, List AF, Fenaux P, Komrokji RS. Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidine. Leuk Res. 2013 Jun;37(6):609-613.

Khan SN, Jankowska AM, Mahfouz R, Dunbar AJ, Sugimoto Y, Hosono N, Hu Z, Cheriyath V, Vatolin S, Przychodzen B, Reu FJ, Saunthararajah Y, O'Keefe C, Sekeres MA, List AF, Moliterno AR, McDevitt MA, Maciejewski JP, Makishima H. Multiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in myeloid malignancies. Leukemia. 2013 Jun;27(6):1301-1309.

Ponnaluri VKC, Maciejewski JP, Mukherji M. A mechanistic overview of TET-mediated 5-methylcytosine oxidation. Biochem Biophys Res Commun. 2013 Jun 28;436(2):115-120.



Rajala HLM, Eldfors S, Kuusanmaki H, van Adrichem AJ, Olson T, Lagstrom S, Andersson EI, Jerez A, Clemente MJ, Yan Y, Zhang D, Awwad A, Ellonen P, Kallioniemi O, Wennerberg K, Porkka K, Maciejewski JP, Loughran TP, Jr., Heckman C, Mustjoki S. Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia. Blood. 2013 May 30;121(22):4541-4550.

Yang L, Mailloux A, Rollison DE, Painter JS, Maciejewski J, Paquette RL, Loughran TP, McGraw K, Makishima H, Radhakrishnan R, Wei S, Ren X, Komrokji R, List AF, Epling-Burnette PK. Naive T-cells in myelodysplastic syndrome display intrinsic human telomerase reverse transcriptase (hTERT) deficiency. Leukemia. 2013 Apr;27(4):897-906.

Mahfouz RZ, Jankowska A, Ebrahem Q, Gu X, Visconte V, Tabarroki A, Terse P, Covey J, Chan K, Ling Y, Engelke KJ, Sekeres MA, Tiu R, Maciejewski J, Radivoyevitch T, Saunthararajah Y. Increased CDA expression/activity in males contributes to decreased cytidine analog half-life and likely contributes to worse outcomes with 5-azacytidine or decitabine therapy. Clin Cancer Res. 2013 Feb 15;19(4):938-948.

Nischal S, Bhattacharyya S, Christopeit M, Yu Y, Zhou L, Bhagat TD, Sohal D, Will B, Mo Y, Suzuki M, Pardanani A, McDevitt M, Maciejewski JP, Melnick AM, Greally JM, Steidl U, Moliterno A, Verma A. Methylome profiling reveals distinct alterations in phenotypic and mutational subgroups of myeloproliferative neoplasms. Cancer Res. 2013 Feb 1;73(3):1076-1085.

Otrock ZK, Tiu RV, Maciejewski JP, Sekeres MA. The need for additional genetic markers for myelodysplastic syndrome stratification: what does the future hold for prognostication? Expert Rev Hematol. 2013 Feb;6(1):59-68.

Wei S, Chen X, McGraw K, Zhang L, Komrokji R, Clark J, Caceres G, Billingsley D, Sokol L, Lancet J, Fortenbery N, Zhou J, Eksioglu EA, Sallman D, Wang H, Epling-Burnette PK, Djeu J, Sekeres M, Maciejewski JP, List A. Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletion. Oncogene. 2013 Feb 28;32(9):1110-1120.

Kar SA, Jankowska A, Makishima H, Visconte V, Jerez A, Sugimoto Y, Muramatsu H, Traina F, Afable M, Guinta K, Tiu RV, Przychodzen B, Sakaguchi H, Kojima S, Sekeres MA, List AF, McDevitt MA, Maciejewski JP. Spliceosomal gene mutations are frequent events in the diverse mutational spectrum of chronic myelomonocytic leukemia but largely absent in juvenile myelomonocytic leukemia. Haematologica. 2013 Jan;98(1):107-113.

Singh H, Lane AA, Correll M, Przychodzen B, Sykes DB, Stone RM, Ballen KK, Amrein PC, Maciejewski J, Attar EC. Putative RNA-splicing gene LUC7L2



on 7q34 represents a candidate gene in pathogenesis of myeloid malignancies. Blood Cancer J. 2013;3:e117.

Sakaguchi H, Makishima H, Muramatsu H, Visconte V, Jerez A, Jankowska AM, Tiu RV, Maciejewski JP, Kojima S. Mutational analysis of RNA splicing machinery components in 206 children with myeloid malignancies. Leuk Res. 2012 Dec;36(12):e215-e217.

Sekeres MA, Tiu RV, Komrokji R, Lancet J, Advani AS, Afable M, Englehaupt R, Juersivich J, Cuthbertson D, Paleveda J, Tabarroki A, Visconte V, Makishima H, Jerez A, Paquette R, List AF, Maciejewski JP. Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes. Blood. 2012 Dec 13;120(25):4945-4951. [PM:22915641].

Visconte V, Makishima H, Maciejewski JP, Tiu RV. Emerging roles of the spliceosomal machinery in myelodysplastic syndromes and other hematological disorders. Leukemia. 2012 Dec;26(12):2447-2454.

Jerez A, Clemente MJ, Makishima H, Koskela H, Leblanc F, Ng KP, Olson T, Przychodzen B, Afable M, Gomez-Segui I, Guinta K, Durkin L, Hsi ED, McGraw K, Zhang D, Wlodarski MW, Porkka K, Sekeres MA, List A, Mustjoki S, Loughran TP, Maciejewski JP. STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia. Blood. 2012 Oct 11;120(15):3048-3057.

Visconte V, Rogers HJ, Singh J, Barnard J, Bupathi M, Traina F, McMahon J, Makishima H, Szpurka H, Jankowska A, Jerez A, Sekeres MA, Saunthararajah Y, Advani AS, Copelan E, Koseki H, Isono K, Padgett RA, Osman S, Koide K, O'Keefe C, Maciejewski JP, Tiu RV. SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes. Blood. 2012 Oct 18;120(16):3173-3186.

Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Levis A, Malcovati L, Cazzola M, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Krieger O, Luebbert M, Maciejewski J, Magalhaes SMM, Miyazaki Y, Pfeilstocker M, Sekeres M, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA, Germing U, Haase D. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012 Sep 20;120(12):2454-2465.

Mailloux AW, Sugimori C, Komrokji RS, Yang L, Maciejewski JP, Sekeres MA, Paquette R, Loughran TP, Jr., List AF, Epling-Burnette PK. Expansion of effector memory regulatory T cells represents a novel prognostic factor in



lower risk myelodysplastic syndrome. J Immunol. 2012 Sep 15;189(6):3198-3208.

Will B, Zhou L, Vogler TO, Ben-Neriah S, Schinke C, Tamari R, Yu Y, Bhagat TD, Bhattacharyya S, Barreyro L, Heuck C, Mo Y, Parekh S, McMahon C, Pellagatti A, Boultwood J, Montagna C, Silverman L, Maciejewski J, Greally JM, Ye BH, List AF, Steidl C, Steidl U, Verma A. Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterations. Blood. 2012 Sep 6;120(10):2076-2086.

Bejanyan N, Tiu RV, Raza A, Jankowska A, Kalaycio M, Advani A, Chan J, Saunthararajah Y, Mooney L, Maciejewski JP, Sekeres MA. A phase 2 trial of combination therapy with thalidomide, arsenic trioxide, dexamethasone, and ascorbic acid (TADA) in patients with overlap myelodysplastic/myeloproliferative neoplasms (MDS/MPN) or primary myelofibrosis (PMF). Cancer. 2012 Aug 15;118(16):3968-3976.

Saito Y, Aoki Y, Muramatsu H, Makishima H, Maciejewski JP, Imaizumi M, Rikiishi T, Sasahara Y, Kure S, Niihori T, Tsuchiya S, Kojima S, Matsubara Y. Casitas B-cell lymphoma mutation in childhood T-cell acute lymphoblastic leukemia. Leuk Res. 2012 Aug;36(8):1009-1015.

Maciejewski JP, Padgett RA. Defects in spliceosomal machinery: a new pathway of leukaemogenesis. Br J Haematol. 2012 Jul;158(2):165-173.

Makishima H, Sugimoto Y, Szpurka H, Clemente MJ, Ng KP, Muramatsu H, O'Keefe C, Saunthararajah Y, Maciejewski JP. CBL mutation-related patterns of phosphorylation and sensitivity to tyrosine kinase inhibitors. Leukemia. 2012 Jul;26(7):1547-1554.

Ratajczak J, Kucia M, Mierzejewska K, Liu R, Kim CH, Natarajan N, Sharma V, Miller DM, Maciejewski J, Ratajczak MZ. A novel view of paroxysmal nocturnal hemoglobinuria pathogenesis: more motile PNH hematopoietic stem/progenitor cells displace normal HSPCs from their niches in bone marrow due to defective adhesion, enhanced migration and mobilization in response to erythrocyte-released sphingosine-1 phosphate gradient. Leukemia. 2012 Jul;26(7):1722-1725.

Jerez A, Sugimoto Y, Makishima H, Verma A, Jankowska AM, Przychodzen B, Visconte V, Tiu RV, O'Keefe CL, Mohamedali AM, Kulasekararaj AG, Pellagatti A, McGraw K, Muramatsu H, Moliterno AR, Sekeres MA, McDevitt MA, Kojima S, List A, Boultwood J, Mufti GJ, Maciejewski JP. Loss of heterozygosity in 7q myeloid disorders: clinical associations and genomic pathogenesis. Blood. 2012 Jun 21;119(25):6109-6117



Germing U, Lauseker M, Hildebrandt B, Symeonidis A, Cermak J, Fenaux P, Kelaidi C, Pfeilstocker M, Nosslinger T, Sekeres M, Maciejewski J, Haase D, Schanz J, Seymour J, Kenealy M, Weide R, Lubbert M, Platzbecker U, Valent P, Gotze K, Stauder R, Blum S, Kreuzer KA, Schlenk R, Ganser A, Hofmann WK, Aul C, Krieger O, Kundgen A, Haas R, Hasford J, Giagounidis A. Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): A multicenter study. Leukemia. 2012 Jun;26(6):1286-1292.

Koskela HL, Eldfors S, Ellonen P, van Adrichem AJ, Kuusanmaki H, Andersson EI, Lagstrom S, Clemente MJ, Olson T, Jalkanen SE, Majumder MM, Almusa H, Edgren H, Lepisto M, Mattila P, Guinta K, Koistinen P, Kuittinen T, Penttinen K, Parsons A, Knowles J, Saarela J, Wennerberg K, Kallioniemi O, Porkka K, Loughran TP, Jr., Heckman CA, Maciejewski JP, Mustjoki S. Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med. 2012 May 17;366(20):1905-1913.

Nyland SB, Krissinger DJ, Clemente MJ, Irby RB, Baab KT, Jarbadan NR, Sokol L, Schaefer E, Liao J, Cuthbertson D, Epling-Burnette P, Paquette R, List AF, Maciejewski JP, Loughran TP, Jr. Seroreactivity to LGL leukemia-specific epitopes in aplastic anemia, myelodysplastic syndrome and paroxysmal nocturnal hemoglobinuria: Results of a bone marrow failure consortium study. Leuk Res. 2012 May;36(5):581-587.

Jerez A, Gondek LP, Jankowska AM, Makishima H, Przychodzen B, Tiu RV, O'Keefe CL, Mohamedali AM, Batista D, Sekeres MA, McDevitt MA, Mufti GJ, Maciejewski JP. Topography, clinical, and genomic correlates of 5q myeloid malignancies revisited. J Clin Oncol. 2012 Apr 20;30(12):1343-1349.

Makishima H, Visconte V, Sakaguchi H, Jankowska AM, Abu KS, Jerez A, Przychodzen B, Bupathi M, Guinta K, Afable MG, Sekeres MA, Padgett RA, Tiu RV, Maciejewski JP. Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis. Blood. 2012 Apr 5;119(14):3203-3210.

Platzbecker U, Santini V, Mufti GJ, Haferlach C, Maciejewski JP, Park S, Sole F, van de Loosdrecht AA, Haase D. Update on developments in the diagnosis and prognostic evaluation of patients with myelodysplastic syndromes (MDS): Consensus statements and report from an expert workshop. Leuk Res. 2012 Mar;36(3):264-270.

Sugimori C, Padron E, Caceres G, Shain K, Sokol L, Zhang L, Tiu R, O'Keefe CL, Afable M, Clemente M, Lee JM, Maciejewski JP, List AF, Epling-Burnette PK, Araten DJ. Paroxysmal nocturnal hemoglobinuria and concurrent JAK2(V617F) mutation. Blood Cancer J. 2012 Mar;2(3):e63.



Visconte V, Makishima H, Jankowska A, Szpurka H, Traina F, Jerez A, O'Keefe C, Rogers HJ, Sekeres MA, Maciejewski JP, Tiu RV. SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts. Leukemia. 2012 Mar;26(3):542-545.

Hama A, Muramatsu H, Makishima H, Sugimoto Y, Szpurka H, Jasek M, O'Keefe C, Takahashi Y, Sakaguchi H, Doisaki S, Shimada A, Watanabe N, Kato K, Kiyoi H, Naoe T, Kojima S, Maciejewski JP. Molecular lesions in childhood and adult acute megakaryoblastic leukaemia. Br J Haematol. 2012 Feb;156(3):316-325.

Maciejewski JP, Haferlach T. Introduction: molecular pathogenesis of hematologic malignancies. Semin Oncol. 2012 Feb;39(1):9-12.

Muramatsu H, Makishima H, Maciejewski JP. Chronic myelomonocytic leukemia and atypical chronic myeloid leukemia: novel pathogenetic lesions. Semin Oncol. 2012 Feb;39(1):67-73.

Negrotto S, Ng KP, Jankowska AM, Bodo J, Gopalan B, Guinta K, Mulloy JC, Hsi E, Maciejewski J, Saunthararajah Y. CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors. Leukemia. 2012 Feb;26(2):244-254.

Saunthararajah Y, Maciejewski J. Polycomb segment myeloid malignancies. Blood. 2012 Feb 2;119(5):1097-1098.

Sugimoto Y, Sekeres MA, Makishima H, Traina F, Visconte V, Jankowska A, Jerez A, Szpurka H, O'Keefe CL, Guinta K, Afable M, Tiu R, McGraw KL, List AF, Maciejewski J. Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide. J Hematol Oncol. 2012;5(1):4.

Traina F, Visconte V, Jankowska AM, Makishima H, O'Keefe CL, Elson P, Han Y, Hsieh FH, Sekeres MA, Mali RS, Kalaycio M, Lichtin AE, Advani AS, Duong HK, Copelan E, Kapur R, Olalla Saad ST, Maciejewski JP, Tiu RV. Single nucleotide polymorphism array lesions, TET2, DNMT3A, ASXL1 and CBL mutations are present in systemic mastocytosis. PLoS ONE. 2012;7(8):e43090.

Ng KP, Ebrahem Q, Negrotto S, Mahfouz RZ, Link KA, Hu Z, Gu X, Advani A, Kalaycio M, Sobecks R, Sekeres M, Copelan E, Radivoyevitch T, Maciejewski J, Mulloy JC, Saunthararajah Y. p53 Independent epigenetic-differentiation treatment in xenotransplant models of acute myeloid leukemia. Leukemia. 2011 Nov;25(11):1739-1750.



Bego MG, Keyes LR, Maciejewski J, St Jeor SC. Human cytomegalovirus latency-associated protein LUNA is expressed during HCMV infections in vivo. Arch Virol. 2011 Oct;156(10):1847-1851.

Clemente MJ, Wlodarski MW, Makishima H, Viny AD, Bretschneider I, Shaik M, Bejanyan N, Lichtin AE, Hsi ED, Paquette RL, Loughran TP, Jr., Maciejewski JP. Clonal drift demonstrates unexpected dynamics of the T-cell repertoire in T-large granular lymphocyte leukemia. Blood. 2011 Oct 20;118(16):4384-4393.

Jankowska AM, Makishima H, Tiu RV, Szpurka H, Huang Y, Traina F, Visconte V, Sugimoto Y, Prince C, O'Keefe C, Hsi ED, List A, Sekeres MA, Rao A, McDevitt MA, Maciejewski JP. Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A. Blood. 2011 Oct 6;118(14):3932-3941.

Stein BL, Williams DM, O'Keefe C, Rogers O, Ingersoll RG, Spivak JL, Verma A, Maciejewski JP, McDevitt MA, Moliterno AR. Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes. Haematologica. 2011 Oct;96(10):1462-1469.

Al-Harbi S, Hill BT, Mazumder S, Singh K, Devecchio J, Choudhary G, Rybicki LA, Kalaycio M, Maciejewski JP, Houghton JA, Almasan A. An antiapoptotic BCL-2 family expression index predicts the response of chronic lymphocytic leukemia to ABT-737. Blood. 2011 Sep 29;118(13):3579-3590.

Afable MG, Shaik M, Sugimoto Y, Elson P, Clemente M, Makishima H, Sekeres MA, Lichtin A, Advani A, Kalaycio M, Tiu RV, O'Keefe CL, Maciejewski JP. Efficacy of rabbit anti-thymocyte globulin in severe aplastic anemia. Haematologica. 2011 Sep;96(9):1269-1275.

Askar M, Sobecks R, Morishima Y, Kawase T, Nowacki A, Makishima H, Maciejewski J. Predictions in the face of clinical reality: HistoCheck versus high-risk HLA allele mismatch combinations responsible for severe acute graft-versus-host disease. Biol Blood Marrow Transplant. 2011 Sep;17(9):1409-1415.

Bodo J, Sedlak J, Maciejewski JP, Almasan A, Hsi ED. HDAC inhibitors potentiate the apoptotic effect of enzastaurin in lymphoma cells. Apoptosis. 2011 Sep;16(9):914-923.

Jankowska AM, Szpurka H, Calabro M, Mohan S, Schade AE, Clemente M, Silverstein RL, Maciejewski JP. Loss of expression of neutrophil proteinase-3:



a factor contributing to thrombotic risk in paroxysmal nocturnal hemoglobinuria. Haematologica. 2011 Jul;96(7):954-962.

Afable MG, II, Wlodarski M, Makishima H, Shaik M, Sekeres MA, Tiu RV, Kalaycio M, O'Keefe CL, Maciejewski JP. SNP array-based karyotyping: differences and similarities between aplastic anemia and hypocellular myelodysplastic syndromes. Blood. 2011 Jun 23;117(25):6876-6884.

Makishima H, Maciejewski JP. Pathogenesis and consequences of uniparental disomy in cancer. Clin Cancer Res. 2011 Jun 15;17(12):3913-3923.

Tiu RV, Visconte V, Traina F, Schwandt A, Maciejewski JP. Updates in cytogenetics and molecular markers in MDS. Curr Hematol Malig Rep. 2011 Jun;6(2):126-135.

Serio B, Selleri C, Maciejewski JP. Impact of immunogenetic polymorphisms in bone marrow failure syndromes. Mini Rev Med Chem. 2011 Jun 1;11(6):544-552.

Kojima S, Nakao S, Young N, Bacigalupo A, Gerard G, Hirano N, Maciejewski J, Deeg J, Marsh J, Zhang FK, Lee JW, Ozawa K. The Third Consensus Conference on the treatment of aplastic anemia. Int J Hematol. 2011 Jun;93(6):832-837.

Makishima H, Jankowska AM, McDevitt MA, O'Keefe C, Dujardin S, Cazzolli H, Przychodzen B, Prince C, Nicoll J, Siddaiah H, Shaik M, Szpurka H, Hsi E, Advani A, Paquette R, Maciejewski JP. CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia. Blood. 2011 May 26;117(21):e198-e206.

Tiu RV, Gondek LP, O'Keefe CL, Elson P, Huh J, Mohamedali A, Kulasekararaj A, Advani AS, Paquette R, List AF, Sekeres MA, McDevitt MA, Mufti GJ, Maciejewski JP. Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignancies. Blood. 2011 Apr 28;117(17):4552-4560.

Feng X, Scheinberg P, Wu CO, Samsel L, Nunez O, Prince C, Ganetzky RD, McCoy JP, Jr., Maciejewski JP, Young NS. Cytokine signature profiles in acquired aplastic anemia and myelodysplastic syndromes. Haematologica. 2011 Apr;96(4):602-606.

Sekeres MA, Maciejewski JP, Erba HP, Afable M, Englehaupt R, Sobecks R, Advani A, Seel S, Chan J, Kalaycio ME. A Phase 2 study of combination



therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemia. Cancer. 2011 Mar 15;117(6):1253-1261.

Pulsipher MA, Young NS, Tolar J, Risitano AM, Deeg HJ, Anderlini P, Calado R, Kojima S, Eapen M, Harris R, Scheinberg P, Savage S, Maciejewski JP, Tiu RV, DiFronzo N, Horowitz MM, Antin JH. Optimization of therapy for severe aplastic anemia based on clinical, biologic, and treatment response parameters: conclusions of an international working group on severe aplastic anemia convened by the blood and marrow transplant clinical trials network, March 2010. Biol Blood Marrow Transplant. 2011 Mar;17(3):291-299.

O'Keefe CL, Sugimori C, Afable M, Clemente M, Shain K, Araten DJ, List A, Epling-Burnette PK, Maciejewski JP. Deletions of Xp22.2 including PIG-A locus lead to paroxysmal nocturnal hemoglobinuria. Leukemia. 2011 Feb;25(2):379-382.

Sekeres MA, O'Keefe C, List AF, Paulic K, Afable M, Englehaupt R, Maciejewski JP. Demonstration of additional benefit in adding lenalidomide to azacitidine in patients with higher-risk myelodysplastic syndromes. Am J Hematol. 2011 Jan;86(1):102-103.

Afable MG, Tiu RV, Maciejewski JP. Clonal evolution in aplastic anemia. Hematology Am Soc Hematol Educ Program. 2011;2011:90-95.

Sekeres MA, Maciejewski JP, List AF, Steensma DP, Artz A, Swern AS, Scribner P, Huber J, Stone R. Perceptions of disease state, treatment outcomes, and prognosis among patients with myelodysplastic syndromes: results from an internet-based survey. Oncologist. 2011;16(6):904-911.

Daniel J. Lindner, MD, PhD

Kalakonda S, Nallar SC, Jaber S, Keay SK, Rorke E, Munivenkatappa R, Lindner DJ, Fiskum GM, Kalvakolanu DV. Monoallelic loss of tumor suppressor GRIM-19 promotes tumorigenesis in mice. Proc Natl Acad Sci U S A. 2013 Nov 5;110(45):E4213-E4222.

Zamanian-Daryoush M, Lindner D, Tallant TC, Wang Z, Buffa J, Klipfell E, Parker Y, Hatala D, Parsons-Wingerter P, Rayman P, Yusufishaq MS, Fisher EA, Smith JD, Finke J, DiDonato JA, Hazen SL. The cardioprotective protein apolipoprotein a1 promotes potent anti-tumorigenic effectss. J Biol Chem. 2013 Jul 19;288(29):21237-21252.

Zhou N, Singh K, Mir MC, Parker Y, Lindner D, Dreicer R, Ecsedy JA, Zhang Z, Teh BT, Almasan A, Hansel DE. The investigational aurora kinase A



inhibitor MLN8237 induces defects in cell viability and cell-cycle progression in malignant bladder cancer cells in vitro and in vivo. Clin Cancer Res. 2013 Apr 1;19(7):1717-1728.

Lindner DJ, Wu Y, Haney R, Jacobs BS, Fruehauf JP, Tuthill R, Borden EC. Thrombospondin-1 expression in melanoma is blocked by methylation and targeted reversal by 5-Aza-deoxycytidine suppresses angiogenesis. Matrix Biol. 2013 Mar 11;32(2):123-132.

Nallar SC, Kalakonda S, Lindner DJ, Lorenz RR, Lamarre E, Weihua X, Kalvakolanu DV. Tumor-derived mutations in the gene associated with retinoid interferon-induced mortality (GRIM-19) disrupt its anti-signal transducer and activator of transcription 3 (STAT3) activity and promote oncogenesis. J Biol Chem. 2013 Mar 15;288(11):7930-7941.

Petty A, Myshkin E, Qin H, Guo H, Miao H, Tochtrop GP, Hsieh JT, Page P, Liu L, Lindner DJ, Acharya C, Mackerell AD, Jr., Ficker E, Song J, Wang B. A small molecule agonist of EphA2 receptor tyrosine kinase inhibits tumor cell migration in vitro and prostate cancer metastasis in vivo. PLoS ONE. 2012;7(8):e42120.

Wu X, Burden-Gulley SM, Yu GP, Tan M, Lindner D, Brady-Kalnay SM, Lu ZR. Synthesis and evaluation of a peptide targeted small molecular Gd-DOTA monoamide conjugate for MR molecular imaging of prostate cancer. Bioconjug Chem. 2012 Aug 15;23(8):1548-1556.

Tan M, Burden-Gulley SM, Li W, Wu X, Lindner D, Brady-Kalnay SM, Gulani V, Lu ZR. MR molecular imaging of prostate cancer with a peptide-targeted contrast agent in a mouse orthotopic prostate cancer model. Pharm Res. 2012 Apr;29(4):953-960.

Niu X, Zhang T, Liao L, Zhou L, Lindner DJ, Zhou M, Rini B, Yan Q, Yang H. The von Hippel-Lindau tumor suppressor protein regulates gene expression and tumor growth through histone demethylase JARID1C. Oncogene. 2012 Feb 9;31(6):776-786

Hjelmeland AB, Wu Q, Heddleston JM, Choudhary GS, Macswords J, Lathia JD, McLendon R, Lindner D, Sloan A, Rich JN. Acidic stress promotes a glioma stem cell phenotype. Cell Death Differ. 2011 May;18(5):829-840.

Hussey GS, Chaudhury A, Dawson AE, Lindner DJ, Knudsen CR, Wilce MCJ, Merrick WC, Howe PH. Identification of an mRNP complex regulating tumorigenesis at the translational elongation step. Mol Cell. 2011 Feb 18;41(4):419-431.



Negrotto S, Hu Z, Alcazar O, Ng KP, Triozzi P, Lindner D, Rini B, Saunthararajah Y. Noncytotoxic differentiation treatment of renal cell cancer. Cancer Res. 2011 Feb 15;71(4):1431-1441.

Patrick Ma, MD, MS

Martin H, Mali RS, Ma P, Chatterjee A, Ramdas B, Sims E, Munugalavadla V, Ghosh J, Mattingly RR, Visconte V, Tiu RV, Vlaar CP, Dharmawardhane S, Kapur R. Pak and Rac GTPases promote oncogenic KIT-induced neoplasms. J Clin Invest. 2013 Oct 1;123(10):4449-4463.

Minca EC, Portier BP, Wang Z, Lanigan C, Farver CF, Feng Y, Ma PC, Arrossi VA, Pennell NA, Tubbs RR. ALK status testing in non-small cell lung carcinoma: Correlation between ultrasensitive IHC and FISH. J Mol Diagn. 2013 May;15(3):341-346.

Feng Y, Ma PC. MET targeted therapy for lung cancer: Clinical development and future directions. Lung Cancer: Targets and Therapy. 2012;3:53-67.

Zhang Z, Lee JC, Lin L, Olivas V, Au V, Laframboise T, Abdel-Rahman M, Wang X, Levine AD, Rho JK, Choi YJ, Choi CM, Kim SW, Jang SJ, Park YS, Kim WS, Lee DH, Lee JS, Miller VA, Arcila M, Ladanyi M, Moonsamy P, Sawyers C, Boggon TJ, Ma PC, Costa C, Taron M, Rosell R, Halmos B, Bivona TG. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet. 2012 Aug;44(8):852-860. [PM:22751098].

El-Telbany A, Ma PC. Cancer genes in lung cancer: racial disparities: are there any? Genes Cancer. 2012 Jul;3(7-8):467-480.

Pennell NA, Yin L, Keshtgarpour M, Ma PC. Two generations of light/never-smokers with advanced adenocarcinoma of the lung with durable responses to erlotinib. J Thorac Oncol. 2012 Jul;7(7):1200-1201

Ma PC. Personalized targeted therapy in advanced non-small cell lung cancer. Cleve Clin J Med. 2012 May;79 Electronic Suppl 1:eS56-eS60.

Schwandt A, Mekhail T, Halmos B, O'Brien T, Ma PC, Fu P, Ivy P, Dowlati A. Phase-II trial of rebeccamycin analog, a dual topoisomerase-I and -II inhibitor, in relapsed "sensitive" small cell lung cancer. J Thorac Oncol. 2012 Apr;7(4):751-754.

Feng Y, Thiagarajan PS, Ma PC. MET signaling: Novel targeted inhibition and its clinical development in lung cancer. J Thorac Oncol. 2012 Feb;7(2):459-467.



Feng Y, Ma PC. Anti-MET targeted therapy has come of age: The first durable complete response with MetMAb in metastatic gastric cancer. Cancer Discov. 2011 Dec;1(7):550-554.

Feng Y, Ma PC. Anti-MET targeted therapy has come of age: the first durable complete response with MetMAb in metastatic gastric cancer. Cancer Discov. 2011 Dec;1(7):550-554.

Mali RS, Ramdas B, Ma P, Shi J, Munugalavadla V, Sims E, Wei L, Vemula S, Nabinger SC, Goodwin CB, Chan RJ, Traina F, Visconte V, Tiu RV, Lewis TA, Stern AM, Wen Q, Crispino JD, Boswell HS, Kapur R. Rho kinase regulates the survival and transformation of cells bearing oncogenic forms of KIT, FLT3, and BCR-ABL. Cancer Cell. 2011 Sep 13;20(3):357-369.

Frederic Reu, MD


Heuck CJ, Mehta J, Bhagat T, Gundabolu K, Yu Y, Khan S, Chrysofakis G, Schinke C, Tariman J, Vickrey E, Pulliam N, Nischal S, Zhou L, Bhattacharyya S, Meagher R, Hu C, Maqbool S, Suzuki M, Parekh S, Reu F, Steidl U, Greally J, Verma A, Singhal SB. Myeloma is characterized by stage-specific alterations in DNA methylation that occur early during myelomagenesis. J Immunol. 2013 Mar 15;190(6):2966-2975.

Vatolin S, Khan SN, Reu FJ. Direct chromatin PCR (DC-PCR): hypotonic conditions allow differentiation of chromatin states during thermal cycling. PLoS ONE. 2012;7(9):e44690.

Siegel DS, Martin T, Wang M, Vij R, Jakubowiak AJ, Lonial S, Trudel S, Kukreti V, Bahlis N, Alsina M, Chanan-Khan A, Buadi F, Reu FJ, Somlo G, Zonder J, Song K, Stewart AK, Stadtmauer E, Kunkel L, Wear S, Wong AF, Orlowski RZ, Jagannath S. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood. 2012 Oct 4;120(14):2817-2825.

Vij R, Wang M, Kaufman JL, Lonial S, Jakubowiak AJ, Stewart AK, Kukreti V, Jagannath S, McDonagh KT, Alsina M, Bahlis NJ, Reu FJ, Gabrail NY, Belch A, Matous JV, Lee P, Rosen P, Sebag M, Vesole DH, Kunkel LA, Wear SM, Wong AF, Orlowski RZ, Siegel DS. An open-label, single-arm, phase 2 (PX-



171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma. Blood. 2012 Jun 14;119(24):5661-5670.

Saunthararajah Y, Triozzi P, Rini B, Singh A, Radivoyevitch T, Sekeres M, Advani A, Tiu R, Reu F, Kalaycio M, Copelan E, Hsi E, Lichtin A, Bolwell B. p53-Independent, normal stem cell sparing epigenetic differentiation therapy for myeloid and other malignancies. Semin Oncol. 2012 Feb;39(1):97-108.

Calabrese C, Faiman B, Martin D, Reu F, Calabrese LH. Type 1 cryoglobulinemia: response to thalidomide and lenalidomide. J Clin Rheumatol. 2011 Apr;17(3):145-147.

Bencsath KP, Reu F, Dietz J, Hsi ED, Heresi GA. Idiopathic systemic capillary leak syndrome preceding diagnosis of infiltrating lobular carcinoma of the breast with quiescence during neoadjuvant chemotherapy. Mayo Clin Proc. 2011 Mar;86(3):260-261.

Yogen Saunthararajah, MD

Ng KP, Hu Z, Ebrahem Q, Negrotto S, Lausen J, Saunthararajah Y. Runx1 deficiency permits granulocyte lineage commitment but impairs subsequent maturation. Oncogenesis. 2013;2:e78.



Mahfouz RZ, Koh LS, Teo M, Chee CL, Toh HC, Saunthararajah Y. Gender, cytidine deaminase, and 5-aza/decitabine--response. Clin Cancer Res. 2013 Jun 1;19(11):3106-3107.



Wunderlich M, Mizukawa B, Chou FS, Sexton C, Shrestha M, Saunthararajah Y, Mulloy JC. AML cells are differentially sensitive to chemotherapy treatment in a human xenograft model. Blood. 2013 Mar 21;121(12):e90-e97.


Radivoyevitch T, Saunthararajah Y, Pink J, Ferris G, Lent I, Jackson M, Junk D, Kunos CA. dNTP supply gene expression patterns after P53 loss. Cancers (Basel). 2012 Nov 20;4(4):1212-1224. [PM:23205301].

Brady A, Gibson S, Rybicki L, Hsi E, Saunthararajah Y, Sekeres MA, Tiu R, Copelan E, Kalaycio M, Sobecks R, Bates J, Advani AS. Expression of phosphorylated signal transducer and activator of transcription 5 is associated with an increased risk of death in acute myeloid leukemia. Eur J Haematol. 2012 Oct;89(4):288-293.

Ebrahem Q, Mahfouz RZ, Ng KP, Saunthararajah Y. High cytidine deaminase expression in the liver provides sanctuary for cancer cells from decitabine treatment effects. Oncotarget. 2012 Oct;3(10):1137-1145.


Aronow M, Sun Y, Saunthararajah Y, Biscotti C, Tubbs R, Triozzi P, Singh AD. Monosomy 3 by FISH in uveal melanoma: Variability in techniques and results. Surv Ophthalmol. 2012 Sep;57(5):463-473.

Triozzi PL, Aldrich W, Achberger S, Ponnazhagan S, Alcazar O, Saunthararajah Y. Differential effects of low-dose decitabine on immune effector and suppressor responses in melanoma-bearing mice. Cancer Immunol Immunother. 2012 Sep;61(9):1441-1450.

Hashmi M, Karan D, Phadke S, Saunthararajah Y, Kambhampati S, Van Veldhuizen P. Prostate cancer immunotherapy: An evolving field. Curr Cancer Ther Rev. 2012;8(4):274-282.



Lavelle D, Vaitkus K, Ruiz MA, Ibanez V, Kouznetsova T, Saunthararajah Y, Mahmud N, DeSimone J. Effect of AGM and fetal liver-derived stromal cell lines on globin expression in adult baboon (P. anubis) bone marrow-derived erythroid progenitors. PLoS ONE. 2012;7(5):e36846.

Singh AD, Aronow ME, Sun Y, Bebek G, Saunthararajah Y, Schoenfield LR, Biscotti CV, Tubbs RR, Triozzi PL, Eng C. Chromosome 3 status in uveal melanoma: a comparison of fluorescence in situ hybridization and single-nucleotide polymorphism array. Invest Ophthalmol Vis Sci. 2012;53(7):3331-3339.


Alcazar O, Achberger S, Aldrich W, Hu Z, Negrotto S, Saunthararajah Y, Triozzi P. Epigenetic regulation by decitabine of melanoma differentiation in vitro and in vivo. Int J Cancer. 2012 Jul 1;131(1):18-29.

Makishima H, Sugimoto Y, Szpurka H, Clemente MJ, Ng KP, Muramatsu H, O'Keefe C, Saunthararajah Y, Maciejewski JP. CBL mutation-related patterns of phosphorylation and sensitivity to tyrosine kinase inhibitors. Leukemia. 2012 Jul;26(7):1547-1554.

Hu Z, Saunthararajah Y. CEBPE activation in PML-RARA cells by arsenic. Blood. 2012 Mar 1;119(9):2177-2179.

Lavelle D, Vaitkus K, Ling Y, Ruiz MA, Mahfouz R, Ng KP, Negrotto S, Smith N, Terse P, Engelke KJ, Covey J, Chan KK, DeSimone J, Saunthararajah Y. Effects of tetrahydrouridine on pharmacokinetics and pharmacodynamics of oral decitabine. Blood. 2012 Feb 2;119(5):1240-1247.

Negrotto S, Ng KP, Jankowska AM, Bodo J, Gopalan B, Guinta K, Mulloy JC, Hsi E, Maciejewski J, Saunthararajah Y. CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors. Leukemia. 2012 Feb;26(2):244-254.

Saunthararajah Y, Maciejewski J. Polycomb segment myeloid malignancies. Blood. 2012 Feb 2;119(5):1097-1098.

Saunthararajah Y, Triozzi P, Rini B, Singh A, Radivoyevitch T, Sekeres M, Advani A, Tiu R, Reu F, Kalaycio M, Copelan E, Hsi E, Lichtin A, Bolwell B.



p53-Independent, normal stem cell sparing epigenetic differentiation therapy for myeloid and other malignancies. Semin Oncol. 2012 Feb;39(1):97-108.


Olivieri NF, Saunthararajah Y, Thayalasuthan V, Kwiatkowski J, Ware RE, Kuypers FA, Kim HY, Trachtenberg FL, Vichinsky EP. A pilot study of subcutaneous decitabine in beta-thalassemia intermedia. Blood. 2011 Sep 8;118(10):2708-2711.

Zhou L, Opalinska J, Sohal D, Yu Y, Mo Y, Bhagat T, Abdel-Wahab O, Fazzari M, Figueroa M, Alencar C, Zhang J, Kambhampati S, Parmar S, Nischal S, Hueck C, Suzuki M, Freidman E, Pellagatti A, Boultwood J, Steidl U, Sauthararajah Y, Yajnik V, McMahon C, Gore SD, Platanias LC, Levine R, Melnick A, Wickrema A, Greally JM, Verma A. Aberrant epigenetic and genetic marks are seen in myelodysplastic leukocytes and reveal Dock4 as a candidate pathogenic gene on chromosome 7q. J Biol Chem. 2011 Jul 15;286(28):25211-25223.

Hu Z, Gu X, Baraoidan K, Ibanez V, Sharma A, Kadkol S, Munker R, Ackerman S, Nucifora G, Saunthararajah Y. RUNX1 regulates corepressor interactions of PU.1. Blood. 2011 Jun 16;117(24):6498-6508.

Saraf S, Farooqui M, Infusino G, Oza B, Sidhwani S, Gowhari M, Vara S, Gao W, Krauz L, Lavelle D, DeSimone J, Molokie R, Saunthararajah Y. Standard clinical practice underestimates the role and significance of erythropoietin deficiency in sickle cell disease. Br J Haematol. 2011 May;153(3):386-392.

Brady AK, Fu AZ, Earl M, Kalaycio M, Advani A, Saunthararajah Y, Sobecks R, Copelan E, Sekeres MA. Race and intensity of post-remission therapy in acute myeloid leukemia. Leuk Res. 2011 Mar;35(3):346-350.

Torres V, Triozzi P, Eng C, Tubbs R, Schoenfiled L, Crabb JW, Saunthararajah Y, Singh AD. Circulating tumor cells in uveal melanoma. Future Oncol. 2011 Jan;7(1):101-109.

Ramon Tiu, MD

Shivarov V, Gueorguieva R, Stoimenov A, Tiu R. DNMT3A mutation is a poor prognosis biomarker in AML: Results of a meta-analysis of 4500 AML patients. Leuk Res. 2013 Nov;37(11):1445-1450.



Martin H, Mali RS, Ma P, Chatterjee A, Ramdas B, Sims E, Munugalavadla V, Ghosh J, Mattingly RR, Visconte V, Tiu RV, Vlaar CP, Dharmawardhane S, Kapur R. Pak and Rac GTPases promote oncogenic KIT-induced neoplasms. J Clin Invest. 2013 Oct 1;123(10):4449-4463.


Visconte V, Tabarroki A, Rogers HJ, Hasrouni E, Traina F, Makishima H, Hamilton BK, Liu Y, O'Keefe C, Lichtin A, Horwitz L, Sekeres MA, Hsieh FH, Tiu RV. SF3B1 mutations are infrequently found in non-myelodysplastic bone marrow failure syndromes and mast cell diseases but, if present, are associated with the ring sideroblast phenotype. Haematologica. 2013 Sep;98(9):e105-e107.





Bejar R, Tiu RV, Sekeres MA, Komrokji RS. Myelodysplastic syndromes: Recent advances in risk stratification and unmet therapeutic challenges. Am Soc Clin Oncol Educ Book. 2013;2013:256-270.



Sakaguchi H, Makishima H, Muramatsu H, Visconte V, Jerez A, Jankowska AM, Tiu RV, Maciejewski JP, Kojima S. Mutational analysis of RNA splicing machinery components in 206 children with myeloid malignancies. Leuk Res. 2012 Dec;36(12):e215-e217.




Tabarroki A, Tiu RV. Immunomodulatory agents in myelofibrosis. Expert Opin Investig Drugs. 2012 Aug;21(8):1141-1154.

Tiu R, Kalaycio M. Targeted therapy for patients with chronic myeloid leukemia: clinical trial experience and challenges in inter-trial comparisons. Leuk Lymphoma. 2012 Jul;53(7):1263-1272.

Jerez A, Sugimoto Y, Makishima H, Verma A, Jankowska AM, Przychodzen B, Visconte V, Tiu RV, O'Keefe CL, Mohamedali AM, Kulasekararaj AG, Pellagatti A, McGraw K, Muramatsu H, Moliterno AR, Sekeres MA, McDevitt MA, Kojima S, List A, Boultwood J, Mufti GJ, Maciejewski JP. Loss of heterozygosity in 7q myeloid disorders: clinical associations and genomic pathogenesis. Blood. 2012 Jun 21;119(25):6109-6117.





Portell CA, Sekeres MA, Rogers HJ, Tiu RV. De Novo polycythaemia vera arising 5 years following acute myeloid leukemia remission: suggestion of a chemotherapy resistant JAK2 clone. Br J Haematol. 2012 Apr;157(2):266-267.

Reikvam H, Tiu RV. Venous thromboembolism in patients with essential thrombocythemia and polycythemia vera. Leukemia. 2012 Apr;26(4):563-571. [PM:22076463].

Stein BL, Tiu RV. Biological rationale and clinical use of interferon in the classical BCR-ABL-negative myeloproliferative neoplasms. J Interferon Cytokine Res. 2013 Apr;33(4):145-153.

Sugimori C, Padron E, Caceres G, Shain K, Sokol L, Zhang L, Tiu R, O'Keefe CL, Afable M, Clemente M, Lee JM, Maciejewski JP, List AF, Epling-Burnette PK, Araten DJ. Paroxysmal nocturnal hemoglobinuria and concurrent JAK2(V617F) mutation. Blood Cancer J. 2012 Mar;2(3):e63.


Saunthararajah Y, Triozzi P, Rini B, Singh A, Radivoyevitch T, Sekeres M, Advani A, Tiu R, Reu F, Kalaycio M, Copelan E, Hsi E, Lichtin A, Bolwell B. p53-Independent, normal stem cell sparing epigenetic differentiation therapy for myeloid and other malignancies. Semin Oncol. 2012 Feb;39(1):97-108

Mukherjee S, Tiu RV, Sekeres MA. Blood consult: treating del(5q) myelodysplastic syndromes. Blood. 2012 Jan 12;119(2):342-344.


Traina F, Visconte V, Jankowska AM, Makishima H, O'Keefe CL, Elson P, Han Y, Hsieh FH, Sekeres MA, Mali RS, Kalaycio M, Lichtin AE, Advani AS,



Duong HK, Copelan E, Kapur R, Olalla Saad ST, Maciejewski JP, Tiu RV. Single nucleotide polymorphism array lesions, TET2, DNMT3A, ASXL1 and CBL mutations are present in systemic mastocytosis. PLoS ONE. 2012;7(8):e43090.

Visconte V, Makishima H, Maciejewski JP, Tiu RV. Emerging roles of the spliceosomal machinery in myelodysplastic syndromes and other hematological disorders. Leukemia. 2012 Dec;26(12):2447-2454.

Tiu RV, Sekeres MA. Lenalidomide in del 5q MDS: Responses and side effects revisited. Leuk Res. 2011 Nov;35(11):1440-1441.




Mali RS, Ramdas B, Ma P, Shi J, Munugalavadla V, Sims E, Wei L, Vemula S, Nabinger SC, Goodwin CB, Chan RJ, Traina F, Visconte V, Tiu RV, Lewis TA, Stern AM, Wen Q, Crispino JD, Boswell HS, Kapur R. Rho kinase regulates the survival and transformation of cells bearing oncogenic forms of KIT, FLT3, and BCR-ABL. Cancer Cell. 2011 Sep 13;20(3):357-369.

Tiu RV, Traina F, Sekeres MA. Clofarabine for myelodysplastic syndromes. Expert Opin Investig Drugs. 2011 Jul;20(7):1005-1014.




Tiu RV, Visconte V, Traina F, Schwandt A, Maciejewski JP. Updates in cytogenetics and molecular markers in MDS. Curr Hematol Malig Rep. 2011 Jun;6(2):126-135.


Afable MG, Tiu RV, Maciejewski JP. Clonal evolution in aplastic anemia. Hematology Am Soc Hematol Educ Program. 2011;2011:90-95.

Pulsipher MA, Young NS, Tolar J, Risitano AM, Deeg HJ, Anderlini P, Calado R, Kojima S, Eapen M, Harris R, Scheinberg P, Savage S, Maciejewski JP, Tiu RV, DiFronzo N, Horowitz MM, Antin JH. Optimization of therapy for severe aplastic anemia based on clinical, biologic, and treatment response parameters: conclusions of an international working group on severe aplastic anemia convened by the blood and marrow transplant clinical trials network, march 2010. Biol Blood Marrow Transplant. 2011;17(3):291-299.

Pierre L. Triozzi, MD

Triozzi PL, Fernandez AP. The role of the immune response in Merkel cell carcinoma. Cancers (Basel). 2013;5(1):234-254.

Brenner AJ, Cohen YC, Breitbart E, Bangio L, Sarantopoulos J, Giles FJ, Borden EC, Harats D, Triozzi PL. Phase I dose-escalation study of VB-111, an antiangiogenic virotherapy, in patients with advanced solid tumors. Clin Cancer Res. 2013 Jul 15;19(14):3996-4007.

Triozzi PL, Elson P, Aldrich W, Achberger S, Tubbs R, Biscotti CV, Singh AD. Elevated blood beta-2 microglobulin is associated with tumor monosomy-3 in patients with primary uveal melanoma. Melanoma Res. 2013 Feb;23(1):1-7.

Triozzi PL, Achberger S, Aldrich W, Singh AD, Grane R, Borden EC. The association of blood angioregulatory microRNA levels with circulating endothelial cells and angiogenic proteins in patients receiving dacarbazine and interferon. J Transl Med. 2012 Dec 5;10(1):241. [PM:23217102].

Triozzi PL, Achberger S, Aldrich W, Elson P, Garcia J, Dreicer R. Differential immunologic and microRNA effects of 2 dosing regimens of recombinant human granulocyte/macrophage colony stimulating factor. J Immunother. 2012 Sep;35(7):587-594.



Triozzi PL, Aldrich W, Achberger S, Ponnazhagan S, Alcazar O, Saunthararajah Y. Differential effects of low-dose decitabine on immune effector and suppressor responses in melanoma-bearing mice. Cancer Immunol Immunother. 2012 Sep;61(9):1441-1450.

Aronow M, Sun Y, Saunthararajah Y, Biscotti C, Tubbs R, Triozzi P, Singh AD. Monosomy 3 by FISH in uveal melanoma: Variability in techniques and results. Surv Ophthalmol. 2012 Sep;57(5):463-473.

Singh AD, Aronow ME, Sun Y, Bebek G, Saunthararajah Y, Schoenfield LR, Biscotti CV, Tubbs RR, Triozzi PL, Eng C. Chromosome 3 status in uveal melanoma: a comparison of fluorescence in situ hybridization and single-nucleotide polymorphism array. Invest Ophthalmol Vis Sci. 2012;53(7):3331-3339.

Alcazar O, Achberger S, Aldrich W, Hu Z, Negrotto S, Saunthararajah Y, Triozzi P. Epigenetic regulation by decitabine of melanoma differentiation in vitro and in vivo. Int J Cancer. 2012 Jul 1;131(1):18-29.


Triozzi PL, Singh AD. Blood biomarkers for uveal melanoma. Future Oncol. 2012 Feb;8(2):205-215.

Yi T, Elson P, Mitsuhashi M, Jacobs B, Hollovary E, Budd TG, Spiro T, Triozzi P, Borden EC. Phosphatase inhibitor, sodium stibogluconate, in combination with interferon (IFN) alpha 2b: phase I trials to identify pharmacodynamic and clinical effects. Oncotarget. 2011 Dec;2(12):1155-1164.

Triozzi PL, Aldrich W, Ponnazhagan S. Inhibition and promotion of tumor growth with adeno-associated virus carcinoembryonic antigen vaccine and Toll-like receptor agonists. Cancer Gene Ther. 2011 Dec;18(12):850-858.

Triozzi PL, Borden EC. VB-111 for cancer. Expert Opin Biol Ther. 2011 Dec;11(12):1669-1676.

Schwandt A, Garcia JA, Elson P, Wyckhouse J, Finke JH, Ireland J, Triozzi P, Zhou M, Dreicer R, Rini BI. Clinical and immunomodulatory effects of celecoxib plus Interferon-Alpha in Metastatic Renal Cell Carcinoma patients with COX-2 tumor immunostaining. J Clin Immunol. 2011 Aug;31(4):690-698.



Triozzi PL, Aldrich W, Singh A. Effects of interleukin-1 receptor antagonist on tumor stroma in experimental uveal melanoma. Invest Ophthalmol Vis Sci. 2011;52(8):5529-5535.

Borden EC, Jacobs B, Hollovary E, Rybicki L, Elson P, Olencki T, Triozzi P. Gene regulatory and clinical effects of interferon beta in patients with metastatic melanoma: a phase II trial. J Interferon Cytokine Res. 2011 May;31(5):433-440.

Triozzi PL, Tuthill RJ, Borden E. Re-inventing intratumoral immunotherapy for melanoma. Immunotherapy. 2011 May;3(5):653-671.

Garcia JA, Mekhail T, Elson P, Triozzi P, Nemec C, Dreicer R, Bukowski RM, Rini BI. Clinical and immunomodulatory effects of bevacizumab and low-dose interleukin-2 in patients with metastatic renal cell carcinoma: results from a phase II trial. BJU Int. 2011 Feb;107(4):562-570.

Negrotto S, Hu Z, Alcazar O, Ng KP, Triozzi P, Lindner D, Rini B, Saunthararajah Y. Noncytotoxic differentiation treatment of renal cell cancer. Cancer Res. 2011 Feb 15;71(4):1431-1441.

Torres V, Triozzi P, Eng C, Tubbs R, Schoenfiled L, Crabb JW, Saunthararajah Y, Singh AD. Circulating tumor cells in uveal melanoma. Future Oncol. 2011 Jan;7(1):101-10

Triozzi PL, Singh AD. Blood biomarkers of uveal melanoma metastasis. Br J Ophthalmol. 2011 Jan;95(1):3-4.

Secondary Investigators

Anjali Advani, MD


Lukenbill J, Advani AS. The treatment of adolescents and young adults with acute lymphoblastic leukemia. Curr Hematol Malig Rep. 2013 Jun;8(2):91-97.

Cortes J, Feldman E, Yee K, Rizzieri D, Advani AS, Charman A, Spruyt R, Toal M, Kantarjian H. Two dosing regimens of tosedostat in elderly patients with relapsed or refractory acute myeloid leukaemia (OPAL): a randomised open-label phase 2 study. Lancet Oncol. 2013 Apr;14(4):354-362.



Fayad L, Offner F, Smith MR, Verhoef G, Johnson P, Kaufman JL, Rohatiner A, Advani A, Foran J, Hess G, Coiffier B, Czuczman M, Gine E, Durrant S, Kneissl M, Luu KT, Hua SY, Boni J, Vandendries E, Dang NH. Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-hodgkin lymphoma: Results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab. J Clin Oncol. 2013 Feb 10;31(5):573-583.

Advani AS. Biology and treatment of acute lymphocytic leukemia in adolescents and young adults. Am Soc Clin Oncol Educ Book. 2013;2013:285-289.

Portell CA, Wenzell CM, Advani AS. Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia. Clin Pharmacol. 2013;5(Suppl 1):5-11.

Lazarus HM, Advani AS. When, how, and what cell source for hematopoietic cell transplantation in first complete remission adult acute lymphoblastic leukemia? Hematology Am Soc Hematol Educ Program. 2012;2012:382-388.



Sun D, Elson P, Liedtke M, Medeiros BC, Earl M, Alizadeh A, Bates J, Sekeres MA, Coutre S, Kalaycio M, Sobecks R, Copelan E, Advani AS. Absolute lymphocyte count at day 28 independently predicts event-free and overall survival in adults with newly diagnosed acute lymphoblastic leukemia. Am J Hematol. 2012 Oct;87(10):957-960.





Portell CA, Advani AS. Antibody therapy for acute lymphoblastic leukemia. Curr Hematol Malig Rep. 2012 Jun;7(2):153-159.

Kantarjian H, Thomas D, Jorgensen J, Jabbour E, Kebriaei P, Rytting M, York S, Ravandi F, Kwari M, Faderl S, Rios MB, Cortes J, Fayad L, Tarnai R, Wang SA, Champlin R, Advani A, O'Brien S. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol. 2012 Apr;13(4):403-411.



Stock W, Douer D, DeAngelo DJ, Arellano M, Advani A, Damon L, Kovacsovics T, Litzow M, Rytting M, Borthakur G, Bleyer A. Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel. Leuk Lymphoma. 2011 Dec;52(12):2237-2253.


Advani AS. Blinatumomab: A novel agent to treat minimal residual disease in patients with acute lymphoblastic leukemia. Clin Adv Hematol Oncol. 2011 Oct;9(10):776-777.




Sekeres MA, Gundacker H, Lancet J, Advani A, Petersdorf S, Liesveld J, Mulford D, Norwood T, Willman CL, Appelbaum FR, List AF. A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605. Blood. 2011 Jul 21;118(3):523-528.

Makishima H, Jankowska AM, McDevitt MA, O'Keefe C, Dujardin S, Cazzolli H, Przychodzen B, Prince C, Nicoll J, Siddaiah H, Shaik M, Szpurka H, Hsi E, Advani A, Paquette R, Maciejewski JP. CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia. Blood. 2011 May 26;117(21):e198-e206.

Advani AS, Gibson S, Douglas E, Diacovo J, Elson P, Kalaycio M, Copelan E, Sekeres M, Sobecks R, Sungren S, Lagoo A, Rizzieri D, Hsi E. Histone H4 acetylation by immunohistochemistry and prognosis in relapsed acute lymphocytic leukaemia (ALL). Br J Haematol. 2011 May;153(4):504-507.



Levis M, Ravandi F, Wang ES, Baer MR, Perl A, Coutre S, Erba H, Stuart RK, Baccarani M, Cripe LD, Tallman MS, Meloni G, Godley LA, Langston AA, Amadori S, Lewis ID, Nagler A, Stone R, Yee K, Advani A, Douer D, Wiktor-Jedrzejczak W, Juliusson G, Litzow MR, Petersdorf S, Sanz M, Kantarjian HM, Sato T, Tremmel L, Bensen-Kennedy DM, Small D, Smith BD. Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood. 2011 Mar 24;117(12):3294-3301.

Sekeres MA, Maciejewski JP, Erba HP, Afable M, Englehaupt R, Sobecks R, Advani A, Seel S, Chan J, Kalaycio ME. A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with



myelodysplastic syndromes or secondary acute myeloid leukemia. Cancer. 2011 Mar 15;117(6):1253-1261.

Smith SD, Bolwell BJ, Rybicki LA, Kang T, Dean R, Advani A, Thakkar S, Sobecks R, Kalaycio M, Pohlman B, Sweetenham JW. Comparison of outcomes after auto-SCT for patients with relapsed diffuse large B-cell lymphoma according to previous therapy with rituximab. Bone Marrow Transplant. 2011 Feb;46(2):262-266.

Keith McCrae, MD

McCrae KR. Better late than never? Blood. 2013 Sep 12;122(11):1844-1845.

Kistangari G, McCrae KR. Immune thrombocytopenia. Hematol Oncol Clin North Am. 2013 Jun;27(3):495-520.

McCrae K. Adverse postoperative outcomes in surgical patients with immune thrombocytopenia (Br J Surg 2013; 100: 684-692). Br J Surg. 2013 Apr;100(5):693.

Cheng V, Kashyap SR, Schauer PR, Kirwan JP, McCrae KR. Restoration of glycemic control in patients with type 2 diabetes mellitus after bariatric surgery is associated with reduction in microparticles. Surg Obes Relat Dis. 2013 Mar;9(2):207-212.

Modery-Pawlowski CL, Tian LL, Pan V, McCrae KR, Mitragotri S, Sen Gupta A. Approaches to synthetic platelet analogs. Biomaterials. 2013 Jan;34(2):526-541.

Cines DB, McCrae KR, Zheng XL, Sachais BS, Luning Prak ET, Siegel DL. Antigen and substrate withdrawal in the management of autoimmune thrombotic disorders. Blood. 2012 Nov 15;120(20):4134-4142.

Bentley AA, Merkulov SM, Peng Y, Rozmarynowycz R, Qi X, Pusztai-Carey M, Merrick Langhauser F, Gob E, Kraft P, Geis C, Schmitt J, Brede M, Gobel K, Helluy X, Pham M, Bendszus M, Jakob P, Stoll G, Meuth SG, Nieswandt B, McCrae KR, Kleinschnitz C. Kininogen deficiency protects from ischemic neurodegeneration in mice by reducing thrombosis, blood-brain barrier damage, and inflammation. Blood. 2012 Nov 8;120(19):4082-4092.

WC, Yee VC, McCrae KR, Komar AA. Chimeric glutathione S-transferases containing inserts of kininogen peptides: Potential novel protein therapeutics. J Biol Chem. 2012 Jun 22;287(26):22142-22150.



Despotovic JM, Lambert MP, Herman JH, Gernsheimer TB, McCrae KR, Tarantino MD, Bussel JB. RhIG for the treatment of immune thrombocytopenia: consensus and controversy (CME). Transfusion. 2012 May;52(5):1126-1136.

Allen KL, Fonseca FV, Betapudi V, Willard B, Zhang J, McCrae KR. A novel pathway for human endothelial cell activation by antiphospholipid/anti-beta2 glycoprotein I antibodies. Blood. 2012 Jan 19;119(3):884-893.

John S, McCrae K. Catastrophic antiphospholipid syndrome in a patient with immune thrombocytopenic purpura. Uluslararasi Hematologi-Onkoloji Dergisi : UHOD [International Journal of Hematology and Oncology]. 2011;21(3):200-202.

Allen KL, Hamik A, Jain MK, McCrae KR. Endothelial cell activation by antiphospholipid antibodies is modulated by Kruppel-like transcription factors. Blood. 2011 Jun 9;117(23):6383-6391.

McCrae K. Immune thrombocytopenia: No longer 'idiopathic'. Cleve Clin J Med. 2011 Jun;78(6):358-373.

McCrae KR. Sutton's law and anti-{beta}2GPI antibodies. Blood. 2011 Mar 24;117(12):3253-3255.

Mikkael Sekeres, MD, MS

Kantarjian HM, Sekeres MA, Ribrag V, Rousselot P, Garcia-Manero G, Jabbour EJ, Owen K, Stockman PK, Oliver SD. Phase I study assessing the safety and tolerability of barasertib (azd1152) with low-dose cytosine arabinoside in elderly patients with AML. Clin Lymphoma Myeloma Leuk. 2013 Oct;13(5):559-567

Sekeres MA. Flying without a net in MDS. Blood. 2013 Oct 24;122(17):2925-2926.


Visconte V, Tabarroki A, Rogers HJ, Hasrouni E, Traina F, Makishima H, Hamilton BK, Liu Y, O'Keefe C, Lichtin A, Horwitz L, Sekeres MA, Hsieh FH, Tiu RV. SF3B1 mutations are infrequently found in non-myelodysplastic bone marrow failure syndromes and mast cell diseases but, if present, are



associated with the ring sideroblast phenotype. Haematologica. 2013 Sep;98(9):e105-e107.

Przychodzen B, Jerez A, Guinta K, Sekeres MA, Padgett R, Maciejewski JP, Makishima H. Patterns of missplicing due to somatic U2AF1 mutations in myeloid neoplasms. Blood. 2013 Aug 8;122(6):999-1006.


Sekeres MA. Bone marrow transplantation (BMT) in myelodysplastic syndromes: to BMT or not to BMT--that is the question. J Clin Oncol. 2013 Jul 20;31(21):2643-2644.



Lukenbill J, Rybicki L, Sekeres MA, Zaman MO, Copelan A, Haddad H, Fraser T, Digiorgio MJ, Hanna R, Duong H, Hill B, Kalaycio M, Sobecks R, Bolwell B, Copelan E. Defining incidence, risk factors, and impact on survival of central line-associated blood stream infections following hematopoietic cell transplantation in acute myeloid leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant. 2013 May;19(5):720-724.

Steensma DP, Sekeres MA. Reply to H. Kantarjian et al [Decitabine in older adults with acute myeloid leukemia: Why was the dream broken?]. J Clin Oncol. 2013 May 10;31(14):1796-1797.

Sekeres MA, Stowell SA, Berry CA, Mencia WM, Dancy JN. Improving the diagnosis and treatment of patients with myelodysplastic syndromes through a performance improvement initiative. Leuk Res. 2013 Apr;37(4):422-426.



Sokol L, Cripe L, Kantarjian H, Sekeres MA, Parmar S, Greenberg P, Goldberg SL, Bhushan V, Shammo J, Hohl R, Verma A, Garcia-Manero G, Li YP, Lowe A, Zhu J, List AF. Randomized, dose-escalation study of the p38alpha MAPK inhibitor SCIO-469 in patients with myelodysplastic syndrome. Leukemia. 2013 Apr;27(4):977-980.

Keng MK, Sekeres MA. The race for survival in myelodysplastic syndromes. Leuk Lymphoma. 2013 Feb;54(2):219-220.



Wei S, Chen X, McGraw K, Zhang L, Komrokji R, Clark J, Caceres G, Billingsley D, Sokol L, Lancet J, Fortenbery N, Zhou J, Eksioglu EA, Sallman D, Wang H, Epling-Burnette PK, Djeu J, Sekeres M, Maciejewski JP, List A. Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletion. Oncogene. 2013 Feb 28;32(9):1110-1120.


Sekeres MA, Lancet JE, Wood BL, Grove LE, Sandalic L, Sievers EL, Jurcic JG. Randomized, phase IIb study of low-dose cytarabine and lintuzumab versus low-dose cytarabine and placebo in older adults with untreated acute myeloid leukemia. Haematologica. 2013 Jan;98(1):119-128.

Bejar R, Tiu RV, Sekeres MA, Komrokji RS. Myelodysplastic syndromes: Recent advances in risk stratification and unmet therapeutic challenges. Am Soc Clin Oncol Educ Book. 2013;2013:256-270.



Mukherjee S, Sekeres MA. What's all the fuss about? Facts and figures about bone marrow failure and conditions. Curr Hematol Malig Rep. 2012 Dec;7(4):300-309.


Sekeres MA. Steensma DP. Boulevard of broken dreams: drug approval for older adults with acute myeloid leukemia. J Clin Oncol. 2012 Nov 20;30(33):4061-4063.


Jerez A, Clemente MJ, Makishima H, Koskela H, Leblanc F, Ng KP, Olson T, Przychodzen B, Afable M, Gomez-Segui I, Guinta K, Durkin L, Hsi ED, McGraw K, Zhang D, Wlodarski MW, Porkka K, Sekeres MA, List A, Mustjoki S, Loughran TP, Maciejewski JP. STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia. Blood. 2012 Oct 11;120(15):3048-3057.

Sun D, Elson P, Liedtke M, Medeiros BC, Earl M, Alizadeh A, Bates J, Sekeres MA, Coutre S, Kalaycio M, Sobecks R, Copelan E, Advani AS. Absolute lymphocyte count at day 28 independently predicts event-free and overall survival in adults with newly diagnosed acute lymphoblastic leukemia. Am J Hematol. 2012 Oct;87(10):957-960.


Digiorgio MJ, Fatica C, Oden M, Bolwell B, Sekeres M, Kalaycio M, Akins P, Shane C, Bako J, Gordon SM, Fraser TG. Development of a modified surveillance definition of central line-associated bloodstream infections for



patients with hematologic malignancies. Infect Control Hosp Epidemiol. 2012 Sep;33(9):865-868.

Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Levis A, Malcovati L, Cazzola M, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Krieger O, Luebbert M, Maciejewski J, Magalhaes SMM, Miyazaki Y, Pfeilstocker M, Sekeres M, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA, Germing U, Haase D. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012 Sep 20;120(12):2454-2465.

Mailloux AW, Sugimori C, Komrokji RS, Yang L, Maciejewski JP, Sekeres MA, Paquette R, Loughran TP, Jr., List AF, Epling-Burnette PK. Expansion of effector memory regulatory T cells represents a novel prognostic factor in lower risk myelodysplastic syndrome. J Immunol. 2012 Sep 15;189(6):3198-3208.

O'Brien S, Rizzieri DA, Vey N, Ravandi F, Krug UO, Sekeres MA, Dennis M, Venditti A, Berry DA, Jacobsen TF, Staudacher K, Bergeland T, Giles FJ. Elacytarabine has single-agent activity in patients with advanced acute myeloid leukaemia. Br J Haematol. 2012 Sep;158(5):581-588.


Sekeres MA. Very superstitious. J Clin Oncol. 2012 Aug 20;30(24):3026-3027.

Germing U, Lauseker M, Hildebrandt B, Symeonidis A, Cermak J, Fenaux P, Kelaidi C, Pfeilstocker M, Nosslinger T, Sekeres M, Maciejewski J, Haase D, Schanz J, Seymour J, Kenealy M, Weide R, Lubbert M, Platzbecker U, Valent P, Gotze K, Stauder R, Blum S, Kreuzer KA, Schlenk R, Ganser A, Hofmann WK, Aul C, Krieger O, Kundgen A, Haas R, Hasford J, Giagounidis A. Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): A multicenter study. Leukemia. 2012 Jun;26(6):1286-1292.

Jerez A, Sugimoto Y, Makishima H, Verma A, Jankowska AM, Przychodzen B, Visconte V, Tiu RV, O'Keefe CL, Mohamedali AM, Kulasekararaj AG, Pellagatti A, McGraw K, Muramatsu H, Moliterno AR, Sekeres MA, McDevitt



MA, Kojima S, List A, Boultwood J, Mufti GJ, Maciejewski JP. Loss of heterozygosity in 7q myeloid disorders: clinical associations and genomic pathogenesis. Blood. 2012 Jun 21;119(25):6109-6117.



Portell CA, Sekeres MA, Rogers HJ, Tiu RV. De Novo polycythaemia vera arising 5 years following acute myeloid leukemia remission: suggestion of a chemotherapy resistant JAK2 clone. Br J Haematol. 2012 Apr;157(2):266-267.

Raza A, Galili N, Mulford D, Smith SE, Brown G, Steensma DP, Lyons RM, Boccia R, Sekeres MA, Guillermo GM, Mesa RA. Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS). J Hematol Oncol. 2012 Apr 30;5(1):18.

Raza A, Galili N, Smith SE, Godwin J, Boccia RV, Myint H, Mahadevan D, Mulford D, Rarick M, Brown GL, Schaar D, Faderl S, Komrokji RS, List AF, Sekeres M. A phase 2 randomized multicenter study of 2 extended dosing schedules of oral ezatiostat in low to intermediate-1 risk myelodysplastic syndrome. Cancer. 2012 Apr 15;118(8):2138-2147.

Sekeres MA. How to manage lower-risk myelodysplastic syndromes. Leukemia. 2012 Mar;26(3):390-394.

Sekeres MA. Myelodysplastic syndromes: it is all in the genes. J Clin Oncol. 2012 Mar 10;30(8):774-776.


Wendtner CM, Hillmen P, Mahadevan D, Buhler A, Uharek L, Coutre S, Frankfurt O, Bloor A, Bosch F, Furman RR, Kimby E, Gribben JG, Gobbi M,



Dreisbach L, Hurd DD, Sekeres MA, Ferrajoli A, Shah S, Zhang J, Moutouh-de PL, Hallek M, Heerema NA, Stilgenbauer S, Chanan-Khan AA. Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia. Leuk Lymphoma. 2012 Mar;53(3):417-423.


Sekeres MA. My AML cytogenetics classification scheme is better than yours. Biol Blood Marrow Transplant. 2012 Feb;18(2):160-161.

Mukherjee S, Tiu RV, Sekeres MA. Blood consult: treating del(5q) myelodysplastic syndromes. Blood. 2012 Jan 12;119(2):342-344.

Ornstein MC, Sekeres MA. Combination strategies in myelodysplastic syndromes. Int J Hematol. 2012 Jan;95(1):26-33.



Sekeres MA. The baby whisperer. J Clin Oncol. 2011 Dec 1;29(34):4584-4585.


Tiu RV, Sekeres MA. Lenalidomide in del 5q MDS: Responses and side effects revisited. Leuk Res. 2011 Nov;35(11):1440-1441.




Sekeres MA. Lenalidomide in MDS: 4th time's a charm. Blood. 2011 Oct 6;118(14):3757-3758.

Sekeres MA. The Avastin story. N Engl J Med. 2011 Oct 13;365(15):1454-1455.


Sekeres MA, Steensma DP. A piece of my mind. The road warriors. JAMA. 2011 Aug 24;306(8):805-806.

Sekeres MA, Gundacker H, Lancet J, Advani A, Petersdorf S, Liesveld J, Mulford D, Norwood T, Willman CL, Appelbaum FR, List AF. A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605. Blood. 2011 Jul 21;118(3):523-528.

Tiu RV, Traina F, Sekeres MA. Clofarabine for myelodysplastic syndromes. Expert Opin Investig Drugs. 2011 Jul;20(7):1005-1014.


Komrokji RS, Sekeres MA, List AF. Management of lower-risk myelodysplastic syndromes:the art and evidence. Curr Hematol Malig Rep. 2011 Jun;6(2):145-153.

Sekeres MA, Maciejewski JP, List AF, Steensma DP, Artz A, Swern AS, Scribner P, Huber J, Stone R. Perceptions of disease state, treatment outcomes, and prognosis among patients with myelodysplastic syndromes: results from an internet-based survey. Oncologist. 2011;16(6):904-911.

Sekeres MA. Tricking or treating myelodysplastic syndromes. Oncology (Williston Park). 2011 May;25(6):488, 490, 492.



Advani AS, Gibson S, Douglas E, Diacovo J, Elson P, Kalaycio M, Copelan E, Sekeres M, Sobecks R, Sungren S, Lagoo A, Rizzieri D, Hsi E. Histone H4 acetylation by immunohistochemistry and prognosis in relapsed acute lymphocytic leukaemia (ALL). Br J Haematol. 2011 May;153(4):504-507.



Sekeres MA, Maciejewski JP, Erba HP, Afable M, Englehaupt R, Sobecks R, Advani A, Seel S, Chan J, Kalaycio ME. A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemia. Cancer. 2011 Mar 15;117(6):1253-1261.

Sekeres MA, Kantarjian H, Fenaux P, Becker P, Boruchov A, Guerci-Bresler A, Hu K, Franklin J, Wang YM, Berger D. Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes. Cancer. 2011 Mar 1;117(5):992-1000.

Mutetwa B, Fryzek J, Du Y, Yong M, Sekeres MA, Taioli E. Baseline characteristics and predictors of outcome in patients with myelodysplastic syndromes living in Western Pennsylvania. Leuk Lymphoma. 2011 Feb;52(2):265-272.

Sekeres M. On (cology) language. Oncology Times. 2011 Feb 25;33(4):16.

Sekeres MA. Epidemiology, natural history, and practice patterns of patients with myelodysplastic syndromes in 2010. J Natl Compr Canc Netw. 2011 Jan;9(1):57-63.

Sekeres MA. If Nostradamus were treated for MDS. Blood. 2011 Jan 13;117(2):374-375.

Sekeres MA, O'Keefe C, List AF, Paulic K, Afable M, Englehaupt R, Maciejewski JP. Demonstration of additional benefit in adding lenalidomide to azacitidine in patients with higher-risk myelodysplastic syndromes. Am J Hematol. 2011 Jan;86(1):102-103.

Documents

Translational Hematology and Medical Oncology · Cleveland Clinic Taussig Cancer Institute Department of Translational Hematology and Medical Oncology Journal Publications (2011 to